• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

    2/14/24 9:00:26 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    SC 13G/A 1 p24-0287sc13ga.htm IO BIOTECH, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    IO Biotech, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    449778109

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    þ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 44977810913G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Avoro Capital Advisors LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO, IA

             

     

     

     

     

    CUSIP No. 44977810913G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Behzad Aghazadeh

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 44977810913G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
       
      IO Biotech, Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      Ole Maaløes Vej 3, DK-2200, Copenhagen N, Denmark

     

    Item 2(a). NAME OF PERSON FILING
       
      This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with Avoro, the “Reporting Persons”), who serves as the portfolio manager and controlling person of Avoro.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

     

    Item 2(c). CITIZENSHIP
       
      Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER
       
      449778109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    CUSIP No. 44977810913G/APage 5 of 7 Pages

     

      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    CUSIP No. 44977810913G/APage 6 of 7 Pages

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION
       
      Each Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 44977810913G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 14, 2024

     

    AVORO CAPITAL ADVISORS LLC  
       
       
    /s/ Scott Epstein  
    Name: Scott Epstein  
    Title:

    Chief Financial Officer &

    Chief Compliance Officer

     
       
    /s/ Behzad Aghazadeh  
    BEHZAD AGHAZADEH  

     

     

    Get the next $IOBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

      Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data presented at recent congresses reinforces the potential of the company's T-Win candidates to reshape the tumor microenvironment and drive more effective anti-tumor responsesCompany recognized as one of the most innovative biotechnology companies in the world by Fast Company Company to participate in TD Cowen's 6th Annual Oncology Innovation Summit on May 27 and Jefferies Global Healthcare Conference on June 4, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinica

      5/14/25 8:05:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

      NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on th

      4/26/25 3:05:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

      Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company's lead investigational t

      4/25/25 1:00:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    SEC Filings

    See more
    • SEC Form 10-Q filed by IO Biotech Inc.

      10-Q - IO Biotech, Inc. (0001865494) (Filer)

      5/14/25 8:54:06 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - IO Biotech, Inc. (0001865494) (Filer)

      5/14/25 8:06:21 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

      8-K - IO Biotech, Inc. (0001865494) (Filer)

      4/30/25 4:43:01 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Financials

    Live finance-specific insights

    See more
    • IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

      Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

      3/14/23 4:11:47 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Announces Third Quarter Results for 2022

      Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company's global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma Oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37thAnnual Meeting this week will provide an overview of the Phase 1/2 study (MM1636) with IO102-IO103 in combination with nivolumab for metastatic melanoma and discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 (ARG1) and Transforming Growth Factor Beta 1 (

      11/9/22 4:05:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/26/24 8:50:34 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/23/24 6:56:14 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sullivan Amy bought $8,483 worth of shares (10,250 units at $0.83), increasing direct ownership by 14% to 84,632 units (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/23/24 6:53:56 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Zocca Mai-Britt

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:18:15 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Sullivan Amy

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:16:20 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Smith Devin Whittemore

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:13:48 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

      SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

      11/13/24 5:30:28 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

      SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

      9/17/24 9:01:25 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

      SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

      5/14/24 9:35:27 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    See more

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

      -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

      1/9/25 8:05:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

      NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

      4/15/24 8:30:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

      NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

      4/5/24 8:30:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on IO Biotech with a new price target

      Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00

      11/30/21 7:56:32 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen & Co. initiated coverage on IO Biotech

      Cowen & Co. initiated coverage of IO Biotech with a rating of Outperform

      11/30/21 7:16:27 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on IO Biotech with a new price target

      Jefferies initiated coverage of IO Biotech with a rating of Buy and set a new price target of $20.00

      11/30/21 6:57:41 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care